{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:29:55Z","timestamp":1765229395024,"version":"3.46.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To assess the diagnostic performance of Prostate Imaging for Recurrence Reporting (PI-RR) system using\n                      <jats:sup>68<\/jats:sup>\n                      Ga prostate-specific membrane antigen (PSMA)-11 (HBED-CC) PET\/MRI in prostate cancer (PCa) patients with biochemical recurrence (BCR).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PET\/MRI data of 31 PCa patients [17 with radical prostatectomy (RP) and 14 with radiotherapy (RT)] with BCR were retrospectively analyzed. All patients underwent PSMA PET\/MRI and multiparametric prostate MRI (mpMRI). Images were evaluated using PI-RR system for mpMRI and the European Association of Nuclear Medicine standardized reporting guidelines (E-PSMA) for PET, with PI-RR and E-PSMA scores dichotomized as \u22642 negative and \u22653 positive for recurrence. Diagnostic performances were assessed using expert-based ground truth establishment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sensitivity, specificity, and accuracy were 64.7%, 85.7%, and 74.2%, respectively, for PET and 70.6%, 100%, and 83.9%, respectively, for PI-RR. While PI-RR did not reveal any false positive lesions, five patients with false negative PI-RR results were also negative with PET. In patients with RP, sensitivity, specificity, and accuracy were 44.4%, 100%, and 70.6%, respectively, for PET and 55.6%, 100%, and 76.5%, respectively, for PI-RR. For patients with RT, these values were 87.5%, 66.7%, and 78.6%, respectively, for PET and 87.5%, 100%, and 92.9%, respectively, for PI-RR. There was no significant performance difference between PET or PI-RR in all patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.564), patients with RP (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.317), or RT (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.157).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga PSMA PET evaluation with E-PSMA and mpMRI interpretation with PI-RR have similar diagnostic performance for detection of local recurrence after RP or RT in PCa.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002016","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:02:13Z","timestamp":1750402933000},"page":"895-904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Validation of the Prostate Imaging for Recurrence Reporting (PI-RR) System using 68Ga prostate-specific membrane antigen-11 (HBED-CC) PET\/MRI in biochemical recurrence of prostate cancer: a pilot study"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1868-3957","authenticated-orcid":false,"given":"Lebriz","family":"Uslu-Be\u015fli","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bari\u015f","family":"Bakir","sequence":"additional","affiliation":[{"name":"Department of Radiology, Istanbul Medical Faculty, Istanbul University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selahattin","family":"Durmaz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Gaziosmanpasa Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7etin","family":"Demirda\u011f","sequence":"additional","affiliation":[{"name":"Department of Urology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haluk Bur\u00e7ak","family":"Sayman","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20251208","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20251208","first-page":"87","article-title":"Global cancer statistics, 2012.","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R3-20251208","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R4-20251208","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer.","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"R5-20251208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000000295","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: ASTRO\/AUA guideline amendment 2018-2019.","volume":"202","author":"Pisansky","year":"2019","journal-title":"J Urol"},{"key":"R6-20251208","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0090-4295(02)02268-9","article-title":"Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy.","volume":"61","author":"Freedland","year":"2003","journal-title":"Urology"},{"key":"R7-20251208","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/j.clon.2023.09.012","article-title":"Clinical usefulness of prostate-specific membrane antigen-ligand positron emission tomography\/computed tomography for the detection of prostate cancer biochemical recurrence after primary radiation therapy in patients with prostate-specific antigen below the Phoenix threshold: systematic review and meta-analysis.","volume":"35","author":"Subiela","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R8-20251208","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R9-20251208","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023.","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20251208","first-page":"2753","article-title":"68Ga-PSMA-PET\/CT has a role in detecting prostate cancer lesions in patients with recurrent disease.","volume":"37","author":"Fitzpatrick","year":"2017","journal-title":"Anticancer Res"},{"key":"R11-20251208","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.semnuclmed.2023.07.002","article-title":"PSMA PET for detection of recurrence.","volume":"54","author":"Duan","year":"2024","journal-title":"Semin Nucl Med"},{"key":"R12-20251208","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.22.28665","article-title":"PI-RR: the prostate imaging for recurrence reporting system for MRI assessment of local prostate cancer recurrence after radiation therapy or radical prostatectomy-a review.","volume":"220","author":"Abreu-Gomez","year":"2023","journal-title":"Am J Roentgenol"},{"key":"R13-20251208","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy.","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R14-20251208","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis.","volume":"53","author":"Jeet","year":"2023","journal-title":"Semin Nucl Med"},{"key":"R15-20251208","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI.","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20251208","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1007\/s00330-023-10442-4","article-title":"Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET\/MRI.","volume":"34","author":"Jannusch","year":"2024","journal-title":"Eur Radiol"},{"key":"R17-20251208","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer.","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"R18-20251208","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20251208","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.123.266527","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/CT versus multiparametric MRI for detection of intraprostatic radiorecurrent prostate cancer.","volume":"65","author":"Light","year":"2024","journal-title":"J Nucl Med"},{"key":"R20-20251208","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1148\/radiol.212252","article-title":"Diagnostic accuracy and observer agreement of the MRI prostate imaging for recurrence reporting assessment score.","volume":"304","author":"Pecoraro","year":"2022","journal-title":"Radiology"},{"key":"R21-20251208","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.3390\/cancers14194725","article-title":"Clinical application of the new Prostate Imaging for Recurrence Reporting (PI-RR) score proposed to evaluate the local recurrence of prostate cancer after radical prostatectomy.","volume":"14","author":"Ciccarese","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T20:00:18Z","timestamp":1765224018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002016","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"type":"print","value":"0143-3636"},{"type":"electronic","value":"1473-5628"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}